Production of ²¹¹At and automated radiosynthesis of [²¹¹At]MABG via electrophilic astatodesilylation.

ABSTRACT:

Background

[²¹¹At]m-Astatobenzylguanidine ([²¹¹At]MABG) has demonstrated potent antitumor efficacy in preclinical models of malignant neuroendocrine tumours including neuroblastoma and pheochromocytoma/paraganglioma. The high linear energy transfer and short tissue penetration range of alpha particles enable highly localized cytotoxic effects, potentially overcoming therapeutic limitations associated with conventional beta-emitting radiopharmaceuticals. However, under clinical-scale (i.e., high radioactivity) conditions, the efficient and stable production of [²¹¹At]MABG has been hindered by radiolytic degradation during the manufacturing process limiting the availability of reliable methods offering high radiochemical yield and purity. In this stud

SUBMITTER: Kondo Y 

PROVIDER: S-EPMC12325123 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature